title: Intact-cell-based surface plasmon resonance measurements for ligand affinity evaluation of a membrane receptor.
abstract: Toward future applications to the discovery of drugs against membrane receptors on pathological cells, an intact-cell-based surface plasmon resonance (SPR) methodology has been developed. The injection of a suspension of epidermal carcinoma A431 cells (5×10(7)cells/ml), as an analyte, generated clear SPR responses to epidermal growth factor (EGF) immobilized on the sensor chip. Because the responses were competitively reduced by the free ligand EGF, added to the analyte cell suspension, they certainly reflect the specific interaction of the immobilized EGF with the extracellular region of its receptor, which is highly expressed on the surface of the A431 cells.
authors: Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
authors: Takaaki
authors: T
authors: Mizuguchi
authors: Hiromasa
authors: H
authors: Uchimura
authors: Hiroshi
authors: H
authors: Kataoka
authors: Kenichi
authors: K
authors: Akaji
authors: Yoshiaki
authors: Y
authors: Kiso
authors: Kazuki
authors: K
authors: Saito
mesh_terms: D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism*; D004815:Epidermal Growth Factor / Q000737:chemistry / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D005110:Extracellular Space / Q000378:metabolism; D006801:Humans; D055767:Immobilized Proteins / Q000737:chemistry / Q000378:metabolism; D008024:Ligands; D011485:Protein Binding; D020349:Surface Plasmon Resonance / Q000379:methods*
chemical_list: D055767:Immobilized Proteins; D008024:Ligands; D004815:Epidermal Growth Factor; D066246:ErbB Receptors